Marc Berger: Regarding trying to align RWE methodology with an RCT, what’s the downside? Does it risk the design defining the objective rather than the objective defining the design?

Written by The Evidence Base

In this ‘Patti’s People’ episode, Patti Peeples of the The Peeples Collaborative speaks with Marc Berger, former Pharma Executive and Independent Consultant for real-world data and real-world evidence. View more Patti's People episodes here. Marc Berger Former Pharma Executive and Independent Consultant for real-world data and real-world evidence Marc L. Berger, MD, is a semi-retired, part-time consultant and scientific advisor. Until July 2017, he was Vice President, Real-World Data and Analytics at Pfizer, Inc. Marc has held senior-level positions in industry including Executive Vice President and Senior Scientist at OptumInsight; Vice President, Global Health Outcomes at Eli Lilly and Company;...

To view this content, please register now for access

It's completely free